Mesoblast Limited American Depositary Shares (MESO) is a publicly traded Healthcare sector company. As of May 21, 2026, MESO trades at $14.34 with a market cap of $1.89B and a P/E ratio of 0.00. MESO moved -0.10% today. Year to date, MESO is -20.61%; over the trailing twelve months it is +25.82%. Its 52-week range spans $7.09 to $22.00. Analyst consensus is buy with an average price target of $35.00. Rallies surfaces MESO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Mesoblast Reports US$30.3M Ryoncil Revenues and Hits Phase 3 Back Pain Trial Target: Mesoblast generated US$30.3 million in Ryoncil net revenues and reduced net operating cash spend to US$4.1 million in the quarter, ending with US$122 million of cash on hand. The company achieved patient recruitment targets in its pivotal Phase 3 chronic low back pain trial and secured a CAR technology license.
| Metric | Value |
|---|---|
| Price | $14.34 |
| Market Cap | $1.89B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.00 |
| 52-Week Low | $7.09 |
| Volume | 1.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover MESO: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $35.00.